114 related articles for article (PubMed ID: 1382551)
1. Treatment of poor-risk germ-cell tumors with high-dose cisplatin and etoposide combined with bleomycin.
Daugaard G; Rørth M
Ann Oncol; 1992 Apr; 3(4):277-82. PubMed ID: 1382551
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
[TBL] [Abstract][Full Text] [Related]
3. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.
Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB
Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
5. Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen?
Einhorn LH; Foster RS
J Clin Oncol; 2006 Jun; 24(16):2597-8; author reply 2598-9. PubMed ID: 16735718
[No Abstract] [Full Text] [Related]
6. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.
Nichols CR; Williams SD; Loehrer PJ; Greco FA; Crawford ED; Weetlaufer J; Miller ME; Bartolucci A; Schacter L; Einhorn LH
J Clin Oncol; 1991 Jul; 9(7):1163-72. PubMed ID: 1710655
[TBL] [Abstract][Full Text] [Related]
7. High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors.
Daugaard G; Rŗth M
Eur J Cancer Clin Oncol; 1986 Apr; 22(4):477-85. PubMed ID: 2426115
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.
Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC
J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619
[TBL] [Abstract][Full Text] [Related]
9. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
10. Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poor-risk non-seminomatous germ cell tumors.
Gerl A; Clemm C; Hentrich M; Hartenstein R; Wilmanns W
Acta Oncol; 1993; 32(5):541-6. PubMed ID: 7692901
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
12. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
Williams SD; Birch R; Einhorn LH; Irwin L; Greco FA; Loehrer PJ
N Engl J Med; 1987 Jun; 316(23):1435-40. PubMed ID: 2437455
[TBL] [Abstract][Full Text] [Related]
13. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
15. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma.
Peckham MJ; Horwich A; Blackmore C; Hendry WF
Cancer Treat Rep; 1985 May; 69(5):483-8. PubMed ID: 2408750
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
17. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
18. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
20. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]